All FDA drug approvals

FDA approval · Drugs@FDA

PREVACID 24 HRlansoprazole

NDA022327 ·

FDA approved the original new drug application for PREVACID 24 HR on May 18, 2009, sponsored by PERRIGO PHARMA INTL. FDA’s record shows no approved efficacy supplement on the application since.

Application
NDA022327
Sponsor
PERRIGO PHARMA INTL
Original approval
Review
standard review
Submission class
Type 5 - New Formulation or New Manufacturer
Active ingredient
lansoprazole

Products under this application

Ingredient and strengthFormRouteMarketing status
lansoprazole 15MGCAPSULE, DELAYED REL PELLETSORALOver-the-counter

Approved efficacy supplements

An efficacy supplement is how a sponsor asks FDA to approve a change that needs clinical evidence — most often a new indication. FDA’s record gives each one a submission number, a date and a review priority. It does not say what any supplement approved, so neither does this page. The approval letter and label for each are on accessdata.fda.gov under the application number.

FDA’s record shows no approved efficacy supplement on this application.

FDA records other approved supplements on this application, by the class code it assigns them: Labeling 16 · Manufacturing (CMC) 2. Those are changes to the label or to how the drug is made rather than new clinical evidence, so they are counted here and not listed.

Source: FDA’s Drugs@FDA application file, via openFDA (export 2026-09-03). Every field on this page comes from that record.

Other approvals to PERRIGO PHARMA INTL

An approval date is the start of the question, not the end

What a drug is worth to the company that owns it depends on what else is in the pipeline, how much cash is behind it and who else is running the same trial. FuzeBio reads a biotech end to end on demand — pipeline in plain English, trial design and endpoints, competitors, the cash position, and a valuation with its assumptions on the page. Moderna’s report is open in full, no account.

Open the Moderna report

A complete sample report — nothing held back, no sign-up.